Interstitial Cystitis / bladder pain syndrome pose quite a high treatment burden for patients in terms of both cost and duration. A definite diagnosis of IC/ BPS is still tricky, and the indication remains highly misdiagnosed, especially in men.
Often, misdiagnosis leads to the initiation of the treatment regimen of other indications, which eventually adds to the overall cost burden faced by patients. However, the Interstitial Cystitis market comprises a robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly and provide a better treatment option for people affected with it.
Some of the key pharma companies in the Interstitial cystitis market includes KYORIN Pharmaceutical Co., Ltd., UCB, Lipella Pharmaceuticals Inc., Grünenthal Group, Astellas Pharma US, Seikagaku Corporation and many others.
For more details visit:https://www.delveinsight.com/blog/interstitial-cystitis-market/